Curevac N V (CVAC) Return on Assets ROA from the second quarter of 2025 to second quarter of 2024 and for the year 2025, Average High and Low, Fundamental Ratios from Jun 30 2025 to 0 - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Curevac N v   (NASDAQ: CVAC)


Curevac N V 's ROA from the second quarter of 2025 to the second quarter of 2024 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics


What is Curevac N V 's ROA in the second quarter of 2025?
Curevac N v achieved a return on average assets (ROA) of 25.13 % in its second quarter of 2025, this is above CVAC's average return on assets of -13.77%.
Curevac N V assets over the 12 months ending in its second quarter of 2025 are valued at $827 million

Despite the company's net income deteriorating, Curevac N V was able to improve its ROA compared to the first quarter of 2025.

However, within the Healthcare sector 49 other companies had a higher return on assets. While return on assets, the total ranking has deteriorated compared to the first quarter of 2025 from to 250.

What is ROA?


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Assets (Jun 30 2025)
II. Quarter		 (Mar 31 2025)
I. Quarter		 (Dec 31 2024)
IV. Quarter		 0
III. Quarter		 0
II. Quarter
Y / Y Total Assets Change -4.37 % -5.42 % 1.75 % 1.81 % 1.47 %
Y / Y Net Income Change - - - - -
Net Income (TTM) in million 208 197 175 123 -301
Return On Assets (TTM) 25.13 % 23.59 % 20.7 % 14.61 % -35.84 %
CVAC's Total Ranking # 250 # # # # 4662
Total Assets (TTM) in million 811 801 847 848 848
Seq. Total Assets Change 1.18 % -5.42 % -0.06 % -0 % 0.07 %
Seq. Net Income Change - - - - -

CVAC's 5 Years Annual ROA >> Back to CVAC Management Effectiveness >> Compare CVAC ROA to its Competitors


Return On Assets Company Ranking
Within: No.
Industry # 20
Sector # 50
Overall # 243

Return On Assets Statistics
High Average Low
20.2 %
-13.77 %
-33.01 %
(Dec 31 2024)   (Dec 31 2023)





Financial Statements
Curevac N V 's Assets $ 811 million CVAC's Balance sheet
Curevac N V 's Income $ -68 million Quarterly CVAC's Income Statement
CVAC's Income by Division See CVAC's Income by Division



Annual Return On Assets (Dec 31 2024)
FY 2024		 (Dec 31 2023)
FY 2023		 (Dec 31 2022)
FY 2022		 (Dec 31 2020)
FY 2020
FY
Y / Y Total Assets Change 1.75 % -9.54 % -45.62 % - -
Total Assets in million 847 833 921 1,693 0
Y / Y Net Income Change - - - - -
Net Income in million 182 -291 -262 -145 0
Annual Return On Assets 21.44 % -34.99 % -28.5 % -8.54 % -

CVAC's 5 Years Annual ROA >> Back to CVAC Management Effectiveness >> Compare CVAC ROA to its Competitors



Comment on CVAC's ROA in the fiscal year ending 2024
In the fiscal year 2024 ROA improved to 21.44 % compared to prior year, due to annual net income growth of % to $181.65 million, while value of Curevac N V 's overall assets grew just by 1.75 % to $847.30 million, compared to $847.30 a year before.


More Return On Assets Ratios
CVAC's' Return on Assets at Yahoo Finance
Major Pharmaceutical Preparations Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
CVAC's Roa Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for CVAC's Competitors
Subscribers only: Roa for Curevac N V 's Suppliers
Subscribers only: Return On Assets for CVAC's Customers

You may also want to know
CVAC's Roi CVAC's Inventory Turnover Ratio CVAC's Growth Rates CVAC's Dividend Comparisons
CVAC's Profitability Ratios CVAC's Asset Turnover Ratio CVAC's Dividend Growth
CVAC's Roe CVAC's Valuation Ratios CVAC's Financial Strength Ratios CVAC's Dividend Payout Ratio



Companies with similar Return On Assets at Jun 30 2025, within Healthcare Sector ROA
Rigel Pharmaceuticals Inc  57.03 %
Seres Therapeutics Inc   54.88 %
Gridai Technologies Corp  53.25 %
Exelixis Inc   48.25 %
Earth Science Tech Inc   44.59 %
Adma Biologics Inc   42.90 %
Coherus Oncology inc   40.76 %
Entera Bio Ltd   40.32 %
Agios Pharmaceuticals Inc   40.12 %
Abeona Therapeutics Inc   39.81 %
Biomx Inc  39.73 %
Dariohealth Corp   39.03 %
Stablecoin Development Corporation  38.52 %
Interpace Biosciences Inc   37.22 %
Cytomx Therapeutics Inc   36.01 %
Medinotec Inc   35.97 %
Siga Technologies Inc  35.65 %
Edwards Lifesciences Corporation  31.53 %
Synlogic Inc   31.51 %
Minerva Neurosciences Inc   31.37 %
Idexx Laboratories Inc  29.89 %
Novavax inc   28.65 %
Ptc Therapeutics inc   28.48 %
Nutriband Inc   26.59 %
Halozyme Therapeutics Inc   26.44 %
Rafael Holdings Inc  25.88 %
Mettler toledo International Inc   25.15 %
Longduoduo Co Ltd  24.60 %
Sbc Medical Group Holdings Incorporated  24.51 %
Catalyst Pharmaceuticals Inc   23.82 %

Date modified: 2026-09-18T16:09:18+00:00


Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.